Open medicine (Warsaw, Poland) · 2026
Evaluation of treatment outcomes for AML patients ineligible for intensive chemotherapy before and after the implementation of VEN/AZA - a retrospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gruber Norea, Singer Josef
Аннотация
OBJECTIVES: Acute myeloid leukemia (AML) predominantly affects older patients, many of whom are ineligible for intensive chemotherapy. Although the VIALE-A trial demonstrated improved survival with azacitidine plus venetoclax, its strict eligibility criteria may limit generalizability to routine clinical practice. We therefore evaluated real-world outcomes at our institution.
METHODS: We conducted a retrospective single-centre cohort study of adult AML patients ineligible for intensive chemotherapy. Patients received azacitidine monotherapy (2014-2018) or azacitidine plus venetoclax (2019-2023). Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier estimates and log-rank tests. VIALE-A eligibility was assessed retrospectively.
RESULTS: 21 patients met the inclusion criteria: 8 received azacitidine alone and 13 azacitidine plus venetoclax. Median age was 79 years. Patients receiving azacitidine plus venetoclax completed more treatment cycles (median 7 vs. 4). Median OS was 12.6 vs. 9.1 months with azacitidine alone (p=0.416). Median PFS was 10.0 vs. 8.1 months, respectively (p=0.707). Overall, only 66 % of patients fulfilled the VIALE-A eligibility criteria.
CONCLUSIONS: Azacitidine plus venetoclax was associated with numerically longer OS and PFS, although differences were not statistically significant. Only two-thirds of patients would have met VIALE-A eligibility criteria, highlighting the challenges of translating trial outcomes into routine practice. Larger multicentre studies are warranted.
METHODS: We conducted a retrospective single-centre cohort study of adult AML patients ineligible for intensive chemotherapy. Patients received azacitidine monotherapy (2014-2018) or azacitidine plus venetoclax (2019-2023). Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier estimates and log-rank tests. VIALE-A eligibility was assessed retrospectively.
RESULTS: 21 patients met the inclusion criteria: 8 received azacitidine alone and 13 azacitidine plus venetoclax. Median age was 79 years. Patients receiving azacitidine plus venetoclax completed more treatment cycles (median 7 vs. 4). Median OS was 12.6 vs. 9.1 months with azacitidine alone (p=0.416). Median PFS was 10.0 vs. 8.1 months, respectively (p=0.707). Overall, only 66 % of patients fulfilled the VIALE-A eligibility criteria.
CONCLUSIONS: Azacitidine plus venetoclax was associated with numerically longer OS and PFS, although differences were not statistically significant. Only two-thirds of patients would have met VIALE-A eligibility criteria, highlighting the challenges of translating trial outcomes into routine practice. Larger multicentre studies are warranted.